AG
AST

Advisor Group’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

Advisor Group’s Portfolio AST Stock Details AST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-53
Closed – – 5523
2018
Q4 		$0 Buy
53
+4
+8% +$4 ﹤0.01% 5468
2018
Q3 		$0 Hold
49
– – ﹤0.01% 5418
2018
Q2 		$0 Hold
49
– – ﹤0.01% 5234
2018
Q1 		$0 Sell
49
-2
-4% -$4 ﹤0.01% 5254
2017
Q4 		$0 Sell
51
-698
-93% -$1.77K ﹤0.01% 5254
2017
Q3 		$2K Sell
749
-40
-5% -$135 ﹤0.01% 4635
2017
Q2 		$2K Buy
789
+740
+1,510% +$2.44K ﹤0.01% 4589
2017
Q1 		$0 Sell
49
-41
-46% -$159 ﹤0.01% 4978
2016
Q4 		$0 Buy
90
+41
+84% +$169 ﹤0.01% 4842
2016
Q3 		$0 Sell
49
-61
-55% -$197 ﹤0.01% 4845
2016
Q2 		$0 Buy
+110
New +$398 ﹤0.01% 4662

Advisor Group's AST Position: Q1 2019 in Review

Advisor Group sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q1 2019, closing a stake of 53 shares.

Advisor Group first reported a position in AST in Q2 2016 and held it in 11 quarters. The position peaked at $2K in Q3 2017. 0 funds tracked by Wall St. Rank hold AST as of Q1 2019.

  • Advisor Group reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q1 2019 after selling out during the quarter.
  • Advisor Group sold 53 Asterias Biotherapeutics Inc. Series A shares in Q1 2019.
  • Advisor Group first reported a position in Asterias Biotherapeutics Inc. Series A in Q2 2016 and held it in 11 quarters.
  • Advisor Group's Asterias Biotherapeutics Inc. Series A position peaked at $2K in Q3 2017.
  • 0 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q1 2019.

Based on Advisor Group's 13F filing for Q1 2019, filed 9 May 2019.